Summary of Product Characteristics

Similar documents
Summary of Product Characteristics

SUMMARYOF PRODUCT CHARACTERISTICS

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms.

Your first choice Pour-On for resistant worms. GENERATIONS OF PARTNERSHIP A SANOFI COMPANY

Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium. Applicant: Dechra Limited

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.

MUTUAL RECOGNITION PROCEDURE DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665

SUMMARY OF PRODUCT CHARACTERISTICS

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml.

Dechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS

NEUROTONE THR 00904/0005 UKPAR

SUMMARY OF PRODUCT CHARACTERISTICS. Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE)

IVOMEC EPRINEX (eprinomectin) Pour-On for Beef and Dairy Cattle

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands

ZOVIRAX Cold Sore Cream

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

4 Clinical Particulars

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Public Assessment Report

Public Assessment Report. Table of Contents

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.

Ascorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Solution for Injection

PACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314

Felimazole 5 mg Coated Tablet

Parasites of Dairy Cattle

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277

ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS

SUMMARY OF PRODUCT CHARACTERISTICS. Paracetamol mg for 1 ml of solution for infusion

Public Assessment Report. Decentralised Procedure

1. NAME OF THE MEDICINAL PRODUCT. Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 capsule contains:

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

SUMMARY OF PRODUCT CHARACTERISTICS

Dectomax (doramectin) Pour-On Antiparasitic 0.5% pour-on solution for cattle 5 mg/ml PRODUCT DESCRIPTION: Dectomax Pour-On solution is a

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3

Calcium Folinate Ebewe Data Sheet

Perfalgan 10 mg/ml, solution for infusion

Why Do Sheep and Goat Fecal Egg Counts

Summary of Product Characteristics Medical Air

DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

CORE SmPC FOR RADIOPHARMACEUTICALS

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

Summary of Product Characteristics Medical Helium

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel

Summary of Product Characteristics

MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.

AQUATIC ANIMAL MEDICINE RECORD BOOK

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP

Share the important information in this Medication Guide with members of your household.

Decentralised Procedure. Public Assessment Report

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

CMP Antibody Production Service

Medicine Record Book

Selected Requirements of Prescribing Information

PL 17871/0208 UKPAR TABLE OF CONTENTS

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178

SUMMARY OF PRODUCT CHARACTERISTICS

MATERIAL SAFETY DATA SHEET

Livestock Notifiable Disease Factsheets Warble Fly

PARACETAMOL 10MG/ML SOLUTION FOR INFUSION PL 20240/0004 UKPAR TABLE OF CONTENTS

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP

Summary of Product Characteristics

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Public Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440

Salbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036

HYDROCORTISONE 10 MG TABLETS

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd

SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS

Arnicare Arnica 30c pillules NR 01175/0181 UKPAR

Questions and answers on serious non-fatal adverse events and reporting rules

Kalms Tablets THR 01074/0235 UKPAR

PACKAGE LEAFLET: INFORMATION FOR THE USER

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS

Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR

Public Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate)

Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

FAMACHA Parasite Monitoring System

Absorption of Drugs. Transport of a drug from the GI tract

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España

Public Assessment Report. Decentralised Procedure

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension

Transcription:

Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 50 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Closantel (as Closantel sodium) 50 mg/ml Excipients For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection 4 CLINICAL PARTICULARS 4.1 Target Species Sheep, cattle. Date Printed 06/07/2011 CRN 7010803 page number: 1

4.2 Indications for use, specifying the target species Sheep Trematodes Fasciola hepatica Fasciola gigantica Nematodes Haemonchus contortus (including benzimidazole-resistant strains) Oesophagostomum columbianum Gaigeria pachyscelis Chabertia ovina Arthropods Oestrus ovis Cattle Trematodes Fasciola hepatica Fasciola gigantica Nematodes Haemonchus placei Bunostomum phlebotomum Oesophagostomum radiatum Arthropods Hypoderma bovis Hypoderma lineatum 4.3 Contraindications None. 4.4 Special warnings for each target species Do not exceed the stated dose. Care should be taken to ensure that all injection procedures are correctly carried out and body weights accurately assessed. Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device. Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Date Printed 06/07/2011 CRN 7010803 page number: 2

4.5 Special precautions for use Special precautions for use in animals None Special precautions to be taken by the person administering the veterinay medicinal product to animals Wash hands after administration. Take care to avoid accidental self-administration. 4.6 Adverse reactions (frequency and seriousness) The solution contains polyvidone. This substance may in very exceptional cases induce hyperacute anaphylactic reactions in cattle. 4.7 Use during pregnancy, lactation or lay Flukiver 50 mg/ml Solution for Injection is safe for use during pregnancy and lactation. However, the product is not permitted for use in animals producing milk for human consumption. See section 4.11. 4.8 Interaction with other medicinal products and other forms of interaction None known. Date Printed 06/07/2011 CRN 7010803 page number: 3

4.9 Amounts to be administered and administration route 2.5 mg/kg sc (1 ml/20 kg BW) Adults Immatures Haemonchus contortus X X Gaigeria pachyscelis X X Oestrus ovis 1 st, 2 nd and 3 rd instar Ticks (Ixodes ricinus) feeding on sheep at the time of treatment ate likely to produce fewer viable eggs. 5 mg/kg sc (1 ml/10 kg BW) Adults Immatures Fasciola hepatica X 6 weeks* Fasciola gigantica X 8 weeks Haemonchus contortus (+ BZ-resistant strains) X X Chabertia ovina X X Oesophagostomum columbianum X X *average efficacy against 6 week immature stages of Fasciola hepatica is 86% in sheep. Cattle 2.5 mg/kg sc (1 ml/20 kg BW) Adults Immatures Fasciola hepatica X Fasciola gigantica X Haemonchus placei X X Bunostomum phlebotomum X Oesophagostomum radiatum X 5 mg/kg sc (1 ml/10 kg BW) Adults Immatures Fasciola hepatica X 6 weeks* Fasciola gigantica X 8 weeks* Haemonchus placei X X Bunostomum phlebotomum X X Oesophagostomum radiatum X X Hypoderma bovis Dermal stages Hypoderma lineatum Dermal stages *average efficacy against 6 week immature stages of Fasciola hepatica is 73% in cattle. Because of its long half-life, closantel will protect for several weeks against re-infections with the following nematodes: Date Printed 06/07/2011 CRN 7010803 page number: 4

Sheep Residual Activity Dose (mg/kg) Protection Period Haemonchus contortus 2.5 2 weeks 5 7 weeks Gaigeria pachyscelis 2.5 3 weeks 5 8 weeks Oestrus ovis 5 8 weeks Cattle Residual Activity Dose (mg/kg) Protection Period Haemonchus placei 2.5 4 weeks 5 6 weeks Bunostomum phlebotom 5 3 weeks Oesophagostomum radiatum 5 2 weeks Method of administration Flukiver 50 mg/ml Solution for Injection is to be given by the subcutaneous route. Inject cattle under the loose skin of the neck and sheep behind the shoulder. To ensure administration of a correct dose, body weight should be determined as accurately as possible. When large volumes have to be injected (more than 20 ml), divide the total volume equally over both neck sizes. 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary Symptoms of acute overdosage are decreased vision or blindness, anorexia, incoordination and general weakness. 4.11 Withdrawal Period(s) A period of 77 days should be observed between the last administration of the drug and the time of slaughtering of animals for human consumption. Not permitted for use in animals producing milk for human consumption, including pregnant animals intended to produce milk for human consumption. 5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES Pharmacotherapeutic group: Anthelmintics, phenol derivatives, including salicylanilides ATCvet Code: QP52AG09 Date Printed 06/07/2011 CRN 7010803 page number: 5

5.1 Pharmacodynamic properties Flukiver 50 mg/ml Solution for Injection contains the salicylanilide closantel, a synthetic antiparasitic agent with high efficacy against liver fluke, haematophagous nematodes and larval stages of some arthropods in sheep and cattle. Ticks feeding on sheep at the time of treatment are likely to produce fewer viable eggs Closantel is an uncoupler of mitochondrial oxidative phosphorylation resulting in inhibition of ATP synthesis. This induces a marked change in the energy metabolism and finally leads to death of the parasite. 5.2 Pharmacokinetic properties Closantel is rapidly absorbed into the systemic circulation with peak plasma levels at 24-48 hours after dosing. In plasma, closantel is bound 99% to albumin. As a result, tissue distribution is very limited. On average, tissue levels are 15 times lower than plasma levels. The elimination half-life of closantel from plasma and tissues is approximately 2 to 4 weeks in sheep and 9 to 21 days in cattle. The drug is poorly metabolised and the main excretion route is in the faeces via the bile. Urinary excretion in negligible. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Propylene Glycol Povidone Citric Acid Monohydrate Sodium Hydroxide Citric Acid Water for Injections 6.2 Incompatibilities None known. 6.3 Shelf-life Shelf-life of the veterinary medicinal product as packaged for sale: 36 months. Shelf-life after first opening the immediate packaging: 28 days 6.4 Special precautions for storage Do not store above 25 o C. Protect from light. 6.5 Nature and composition of immediate packaging Container or pack size: 1 or 4 amber Type I glass vials. Closure: Grey bromobutyl siliconised rubber stopper. Cap: Red coloured aluminium. Contents of each vial: 250 ml aqueous solution. Not all pack sizes may be marketed. Date Printed 06/07/2011 CRN 7010803 page number: 6

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials Any unused product or waste materials should be disposed of in accordance with national requirements. Flukiver 50 mg/ml Solution for Injection should not enter water courses as this may be dangerous to fish and other aquatic organisms. 7 MARKETING AUTHORISATION HOLDER Janssen-Cilag Limited, 50 100 Holmers Farm Way High Wycombe, Buckinghamshire, HP12 4EG, United Kingdom. 8 MARKETING AUTHORISATION NUMBER(S) VPA 10545/010/001 9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 30 th September 2009 10 DATE OF REVISION OF THE TEXT 3rd March 2010 Date Printed 06/07/2011 CRN 7010803 page number: 7